National Cancer Institute is funding research on using programmable synthetic messenger RNA to treat two types of solid tumor cancer. . . . → Read More: NIH Funds Programmable mRNA to Treat Cancer
|
|||||
|
       
  |
Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator. . . . → Read More: Sanofi Acquires mRNA Developer in $3.2B Deal 
A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases. . . . → Read More: Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal 
A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells. . . . → Read More: Pharma, Biotech Partner on Off-the-Shelf Cell Therapies 
Researchers designed a technique to adjust the volume of proteins from gene therapy released into patients, providing more control for complex diseases. . . . → Read More: Fine-Tuning Process Devised for Gene Therapies 
The Food and Drug Administration has authorized a clinical trial of stem cells extracted and cultured from patients to treat their cases of multiple sclerosis. . . . → Read More: FDA Clears Stem Cell Trial for Multiple Sclerosis 
A venture philanthropy group is funding an initiative to find digital data indicators of early onset of Alzheimer’s disease and other forms of dementia. . . . → Read More: Alzheimer’s Digital Biomarkers Project Gains New Funds 
A biotechnology company serving gene therapy developers is opening a manufacturing facility for engineered viruses that deliver gene therapies. . . . → Read More: Biotech Opens Gene Therapy Manufacturing Facility 
A company designing synthetic DNA and RNA says reference materials are available for tests that detect the quickly spreading Covid-19 delta variant. . . . → Read More: Covid-19 Delta Variant Testing Reference Released 
A start-up company creating synthetic blood vessels for transplants, based on research in materials science and cell biology, is raising $2.2 million in seed funds. . . . → Read More: Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds  Comments are closed  Finance, New products  biomedical, biotechnology, chemistry, engineering, entrepreneurs, equity, Europe, investment, life sciences, materials science, medical device, physical sciences, university, venture capital |
||||
|
Copyright © 2021 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |
|||||